Because the cancer cells have progressed from the colon or rectum to other areas of the body, metastatic colorectal cancer (mCRC) presents considerable hurdles in the treatment of cancer. A thorough treatment strategy is necessary for this aggressive form of cancer, which frequently entails surgery, chemotherapy, targeted treatments, and even radiation. Surgery is still the mainstay of treating metastatic colorectal cancer (mCRC), particularly in less advanced cases. As much of the malignant tissue as feasible is removed by the surgeon in an attempt to significantly relieve symptoms and possibly induce a brief remission. Nevertheless, because of the nature of metastatic disease, total removal is frequently impractical, necessitating further therapies. mCRC is frequently treated with chemotherapy. It targets cancer cells that are proliferating quickly throughout the body. Although it can be useful in reducing tumor size and delaying the disease's progression, it frequently has negative side effects such weariness, nausea, and hair loss. The field of mCRC treatment has undergone a revolution thanks to targeted medicines. These medications target particular chemicals or processes that contribute to the development and spread of cancer. For instance, medications that target VEGF or the epidermal growth factor receptor (EGFR) have demonstrated a notable level of success in mCRC. But not every patient responds to these treatments, and resistance may eventually grow. Treating mCRC with immunotherapy—more especially, immune checkpoint inhibitors—is another potential approach. These medications aid the body's ability to identify and combat cancerous cells. They are frequently used in conjunction with other treatments, and although they have demonstrated amazing success in treating other cancers, their effectiveness in treating mCRC is currently being investigated. Keeping patients' quality of life high and managing their adverse effects are essential components of providing care for those with metastatic cancer. Palliative care is essential in managing the psychological and practical effects of advanced cancer for patients and their families, as well as in relieving symptoms like pain. For mCRC treatment options to advance, clinical studies are crucial. They make it possible for researchers to test novel treatments and combinations, which eventually improves patient outcomes. Furthermore, genetic testing of tumors can assist in identifying certain mutations that could influence treatment choices, contributing to the development of a more individualized approach to healthcare. In summary, treating metastatic colorectal cancer necessitates a multidisciplinary approach. Palliative care, immunotherapy, chemotherapy, targeted treatments, and surgery are all essential for controlling the illness and enhancing patient outcomes. Finding more specialized and efficient treatments for this difficult ailment is being aided by ongoing research and clinical trials.